KMTS Overview

Financial Performance: Kestra Medical Technologies reported a 53% increase in revenue for Q2 fiscal 2026, reaching $22.6 million, while gross profit also rose significantly to $11.4 million, leading to an expanded gross margin of 50.6%.

Operating Expenses and Losses: The company faced wider GAAP net losses of $32.8 million, up from $20.6 million in the previous year, with operating expenses increasing to $43.2 million, including non-recurring costs.

Cash Position: As of October 31, 2025, Kestra had $175 million in cash and cash equivalents, not accounting for an additional $148 million from a public offering that closed on December 4, 2025.

Revenue Guidance: Kestra has raised its revenue guidance for fiscal 2026 to $91 million, marking a 52% increase over the previous year's revenue of $59.8 million, following multiple revisions from an initial estimate of $85 million.

Public Offering Details: Kestra Medical Technologies has announced a public offering of 6 million common shares priced at $23.00 each, expected to close around December 4, 2025, with gross proceeds estimated at $138 million.

Use of Proceeds: The net proceeds from the offering will be allocated to advancing wearable medical devices, expanding commercialization, investing in technology development, and supporting working capital.

Financial Performance: Preliminary results for Q2 of fiscal 2026 indicate expected revenue between $22.2 million and $22.6 million, a 52% increase from the previous year, while losses from operations are projected to rise to between $31.6 million and $32.0 million.

Stock Performance: KMTS shares closed at $23.01, down 6.80%, but saw a slight increase to $23.05 in after-hours trading, with a trading volume of approximately 459,000 shares compared to an average of 272,000 shares.